Title: Oncology/Cancer Drugs Market - Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020
1Global Oncology/Cancer Drugs Market Forecast
2013 - 2020
Published Date 24 February 2015 No. of
pages 159
2 Introduction to Oncology/Cancer Drugs Market
Biological drugs based on monoclonal antibodies
(mAbs) have emerged as a preferred option for
treating various cancer types, especially for
blood cancer (leukemia). Rising incidence of
various cancer conditions, growing popularity of
advance therapies (biological and targeted drug
therapies), patents expiration of leading drugs
along with commercialization of biosimilars are
the few factors driving the growth of global
oncology drugs market. However, high cost
involved in new drug development coupled with
threat of failure and adverse effects associated
with cancer drugs therapies would restrain the
growth of the market. Commercialization of
advanced therapeutics such as targeted and
immunotherapies would reduce the negative
influence of restraints and fuel the market
growth. The global oncology drugs market is
expected to reach at 111.9 billion by 2020.
Patent expiration of key cancer drugs such as
Herceptin, Erbitux, Rituxan and Avastin, is
expected to boost the growth of cancer
biosimilars market by 2020. Going further, the
biological therapies are expected to dominate the
market by 2020, due to their high efficacy,
target specific action and less toxicity. Blood
cancer drugs market was the largest revenue
generating segment in 2013 owing to the high cost
of drugs (immunotherapies) used for the treatment
of blood cancer. Geographically, North America,
dominates the market followed by Europe. North
America accounted for about 38 share in the
overall oncology drugs market in 2013 owing to
the heavy investments by multinational companies
in research and development of cancer drugs,
particularly immune therapeutics, favorable
reimbursement policies, and high adoption rate of
immunotherapies. On the other hand, Asia-Pacific
market would grow at the promising CAGR of 8.7
during the forecast period.
3 Introduction
Scope of the Report
Key Benefits
Key Audiences
4 KEY BENEFITS
- The report provides the quantitative analysis of
the current market and estimations through
2013-2020 that assists in identifying the
prevailing market opportunities to capitalize on - The report helps in understanding the strategies
adopted by various companies for gaining market
share in the cancer drugs market - The report provides comprehensive analysis of
factors that drive and restrict the growth of the
cancer drugs market - Market conditions of cancer drugs market across
all geographic regions are comprehensively
analysed - Competitive intelligence (of leading
manufacturers) helps in understanding the
competitive scenario across the geographies - SWOT analysis of the key market players is
provided to illustrate the business strategies
adopted by the companies
5 Table of Contents
- INTRODUCTION
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY
THERAPEUTIC MODALITIES - GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER
TYPES - GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY
- COMPANY PROFILES
6 Global Oncology/Cancer Drugs Market Overview
- Market Definition Scope
- Development of novel immuno-oncology drug
products - Key findings
- Porters five forces analysis
- Value chain analysis
- Government regulations and reimbursement
- Patent analysis
- Market share analysis, 2013
- Clinical trials for oncology drugs
- Market dynamics
7 Global Oncology/Cancer Drugs Market By
Therapeutic Modalities
8 Global Oncology/Cancer Drugs Market By Cancer
Types
9 Global Oncology/Cancer Drugs Market By Geography
North America, Europe, Asia Pacific, LAMEA
10 Company Profiles
- Amgen Inc.
- Johnson and Johnson
- Roche Diagnostics
- GlaxoSmithKline PLC
- Merck Company
- Novartis AG
- Pfizer
- Sanofi
- Eli Lilly and Company
- Celgene Corporation
11 Thank You! For More Details
Visit us at
http//www.alliedmarketresearch.com/oncology-cance
r-drugs-market
Follow Us On